EMA encourages companies to submit type I variations by end- November
Marketing authorisation holders are advised to submit any type IB variations or groupings of type IBs and type IAs by 3rd December 2021 for a start of procedure in 2021
Marketing authorisation holders are advised to submit any type IB variations or groupings of type IBs and type IAs by 3rd December 2021 for a start of procedure in 2021
It is the first U.S. FDA approved novel topical mechanism for acne in nearly 40 years
The NFI is published to promote the rational use of medicines in the country.
Generalized pustular psoriasis is characterized by episodes of widespread eruptions of painful, sterile pustules
Acute therapies continue to report strong growth compared to chronic ones.
In India, MSD has signed non-exclusive licensing agreements with eight pharma companies.
Kymriah, the first-ever FDA-approved CAR-T cell therapy, is currently available in 30 countries in one or more indications
The youngest child in India to survive ECMO after undergoing bone marrow transplant for a rare disease
This funding will help the start-up consolidate its position as a one-stop destination for pet parents as they holistically reimagine the entire pet care ecosystem
Moderate-to-severe plaque psoriasis affects about 35 per cent of patients. A key challenge is that many treatments stop working overtime and symptoms return
Subscribe To Our Newsletter & Stay Updated